A phase II study of capecitabine plus concomitant radiation therapy followed by durvalumab (MEDI4736) as preoperative treatment in rectal cancer: PANDORA study first-stage.

被引：14

作者：

Tamberi, Stefano

Grassi, Elisa

Corbelli, Jody

Papiani, Giorgio

Barbera, Maria Aurelia

Zingaretti, Chiara

Moretti, Chiara Carli

Montroni, Isacco

Petracci, Elisabetta

Caruso, Dora

Nosseir, Sofia

Nanni, Oriana

Frassineti, Giovanni Luca

Di Bartolomeo, Maria

Marzola, Marina

Bonetti, Andrea

Gelsomino, Fabio

Pinto, Carmine

Tassinari, Davide

Ugolini, Giampaolo

机构：

[1] Ospedale Gli Infermi, Faenza, Italy

[2] Infermi Hosp, Faenza, Italy

[3] IRCCS, IRST Meldola, Unita Biostat & Sperimentazioni Clin, Ravenna, Italy

[4] Infermi Hosp, Faenza, Italy

[5] Ist Sci Romagnolo Studio & Cura Tumori IRST IRCCS, Biostat & Clin Trials, Meldola, Italy

[6] Ravenna Hosp, Dept Pathol, Ravenna, Italy

[7] Ist Sci Romagnolo Studio & Cura Tumori IRST IRCSS, Meldola, Italy

[8] Ist Sci Romagnolo Studio & Cura Tumori IRST IRCSS, Med Oncol Unit, Meldola, Italy

[9] Fdn IRCCS Ist Nazl Tumori, Milan, Italy

[10] Univ Ferrara, Ferrara, Italy

[11] Mater Salutis Hosp, Dept Med Oncol, Legnago, Italy

[12] Univ Hosp Modena, Modena, Italy

[13] AUSL IRCCS Reggio Emilia, Med Oncol Unit, Clin Canc Ctr, Reggio Emilia, Italy

[14] Dept Oncol, Rimini, Italy

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期

关键词：

D O I：

10.1200/JCO.2021.39.15_suppl.3607

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3607

引用

页数：3

共 50 条

[1] A phase II study of capecitabine plus concomitant radiation therapy followed by durvalumab (MEDI4736) as preoperative treatment in rectal cancer (PANDORA)
Tamberi, Stefano
Grassi, Elisa
Barbera, Maria Aurelia
Corbelli, Jody
Papiani, Giorgio
Montroni, Isacco
Di Bartolomeo, Maria
Cascinu, Stefano
Marzola, Marina
Bonetti, Andrea
Frassineti, Giovanni
Pinto, Carmine
Zingaretti, Chiara
Nanni, Oriana
Moretti, Chiara Carli
Panzini, Ilaria
Rossi, Giulio
Ugolini, Giampaolo
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
[2] A phase II study of capecitabine plus concomitant radiation therapy followed by durvalumab (MEDI4736) as preoperative treatment in rectal cancer: PANDORA study
Barbera, M. A.
Corbelli, J.
Papiani, G.
Grassi, E.
Ugolini, G.
Montroni, I.
Di Bartolomeo, M.
Cascinu, S.
Marzola, M.
Bonetti, A.
Frassineti, G. L.
Nanni, O.
Zattoni, D.
Ghignone, F.
Taffurelli, G.
Pinto, C.
Moretti, C. Carli
Rossi, G.
Palazzi, S.
Tamberi, S.
ANNALS OF ONCOLOGY, 2019, 30 : 249 - 249
[3] A phase II study of capecitabine plus concomitant radiation therapy followed by durvalumab (MEDI4736) as preoperative treatment in rectal cancer: PANDORA study final results.
Tamberi, Stefano
Grassi, Elisa
Zingaretti, Chiara
Papiani, Giorgio
Pini, Sara
Corbelli, Jody
Di Bartolomeo, Maria
Pietrantonio, Filippo
Frassineti, Giovanni Luca
Passardi, Alessandro
Gelsomino, Fabio
Marzola, Marina
Banzi, Maria
Bonetti, Andrea Vincent
Petracci, Elisabetta
Moretti, Chiara Carli
Banchelli, Isabella
Tassinari, Davide
Ugolini, Giampaolo
Nanni, Oriana
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (17)
[4] Phase II study of durvalumab (MEDI4736) in cancer patients HIV-1-infected.
Gonzalez-Cao, Maria
Moran, Teresa
Dalmau, Judith
Garcia-Corbacho, Javier
Bernabe, Reyes
Juan, Oscar
De Castro, Javier
Blanco, Remei
Meyerhans, Andreas
Blanco, Julia
Karachaliou, Niki
Brander, Christian
Garcia-Prado, Julia
Carrillo, Jorge
Provencio, Mariano
Molina Vila, Miguel Angel
Massuti, Bartomeu
Clotet, Bonaventura
Martinez-Picado, Javier
Rosell, Rafael
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[5] Forthcoming Phase II Study of Durvalumab (MEDI4736) Plus Chemotherapy for Small Cell Lung Cancer with Brain Metastases
Shiraishi, Yoshimasa
Shimose, Takayuki
Tsuchiya-Kawano, Yuko
Ishii, Hidenobu
Daga, Haruko
Ito, Kentaro
Saruwatari, Koichi
Okamoto, Isamu
CANCER MANAGEMENT AND RESEARCH, 2022, 14 : 3449 - 3453
[6] Phase II study of capecitabine-based concomitant chemoradiation followed by durvalumab as a neoadjuvant strategy in locally advanced rectal cancer: the PANDORA trial
Grassi, E.
Zingaretti, C.
Petracci, E.
Corbelli, J.
Papiani, G.
Banchelli, I.
Valli, I.
Frassineti, G. L.
Passardi, A.
Di Bartolomeo, M.
Pietrantonio, F.
Gelsomino, F.
Carandina, I.
Banzi, M.
Martella, L.
Bonetti, A., V
Boccaccino, A.
Molinari, C.
Marisi, G.
Ugolini, G.
Nanni, O.
Tamberi, S.
ESMO OPEN, 2023, 8 (05)
[7] A PHASE II STUDY OF PREOPERATIVE CAPECITABINE AND RADIATION THERAPY IN PATIENTS WITH RECTAL CANCER
Cerezo, L.
Martin Martin, M.
Counago, F.
Martin Angulo, M.
Lopez, M.
Marin, A.
Cruz, A.
Rios, P.
RADIOTHERAPY AND ONCOLOGY, 2008, 88 : S220 - S220
[8] A phase II study of Preoperative capecitabine and radiation therapy in patients with rectal cancer
Desai, Sameer P.
El-Rayes, Basil F.
Ben-Josef, Edgar
Greenson, Joel K.
Knol, James A.
Huang, Emina H.
Griffith, Kent A.
Philip, Philip A.
McGinn, Cornelius J.
Zalupski, Mark M.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2007, 30 (04): : 340 - 345
[9] Preoperative treatment combining capecitabine with radiation therapy in rectal cancer: A GERCOR phase II study
Dupuis, Olivier
Vie, Brigitte
Lledo, Gerard
Hennequin, Christophe
Noirclerc, Monique
Bennamoun, Mohamed
Jacob, Jacques H.
ONCOLOGY, 2007, 73 (3-4) : 169 - 176
[10] Olaparib and durvalumab (MEDI4736) phase II study in patients with metastatic pancreatic cancer and DNA damage repair genes alterations
Macarulla, T.
Castet, F.
Lobo de Mena, M.
Garcia-Carbonero, R.
Martinez de Castro, E.
Munoz Martin, A. J.
Pazo Cid, R. A.
Grana Suarez, B.
Gallego Plazas, J.
Alvarez, R.
Ales Diaz, I. C.
Gallego Jimenez, I.
Laquente, B.
Rodriguez, M.
Garcia Paredes, B.
Cano Osuna, M. T.
Ruiz de Mena, I.
Fabregat-Franco, C.
Espinosa Olarte, P.
Aranda Aguilar, E.
ANNALS OF ONCOLOGY, 2023, 34 : S923 - S923

← 1 2 3 4 5 →